LONDON (Reuters) – London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is under review while talks with the government over incentives continue. “We’re still in discussions with the (UK) government to figure out what type of incentives there may be. […]
Health
AstraZeneca: 450 million pound investment in UK under review amid talks with govt
Audio By Carbonatix
LONDON (Reuters) – London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is under review while talks with the government over incentives continue.
“We’re still in discussions with the (UK) government to figure out what type of incentives there may be. We don’t have anything new to report at this time,” AstraZeneca’s Chief Financial Officer Aradhana Sarin said during a media briefing after the company reported third-quarter results.
When asked if the investment was on hold while these talks continue, Sarin replied: “That’s correct.”
But an AstraZeneca spokesperson told Reuters after the media briefing: “The discussions with the UK Government are ongoing and can not be characterised as on hold. We are reviewing the incentives for investment in the UK.”
($1 = 0.7802 pounds)
(Reporting by Maggie Fick in London and Chandini Monnappa in Bengaluru; Editing by Jan Harvey)